Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGT001 in Retinitis Pigmentosa
NCT06936787Phase 1Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IGT001 in retinitis pigmentosa (RP), sponsored by Shanghai General Hospital. Primary endpoints: Adverse Events or Serious Adverse Events at 1 year and Dose-Limiting Toxicity at 28 days. Started Apr 2025; status: recruiting.
02
Drugs
IGT001
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT06936787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06936787.